Related Experiment Videos
Myasthenia gravis: management issues during pregnancy
Simone Ferrero1, Stefano Pretta, Annamaria Nicoletti
1Department of Obstetrics and Gynaecology, San Martino Hospital, University of Genoa, Largo R. Benzi 1, 16132 Genoa, Italy. simone.ferrero@fastwebnet.it
Summary
Women with myasthenia gravis (MG) can safely manage their condition during pregnancy with available therapies. Close monitoring by healthcare providers is essential for a healthy pregnancy outcome.
Area of Science:
- Neurology
- Obstetrics
- Immunology
Background:
- Myasthenia gravis (MG) commonly affects women during their reproductive years.
- Disease course during pregnancy is unpredictable, with symptom exacerbation often occurring in the first trimester and postpartum.
Purpose of the Study:
- To review the management of myasthenia gravis during pregnancy.
- To highlight safe and effective therapeutic options for pregnant women with MG.
- To emphasize the importance of multidisciplinary care.
Main Methods:
- Review of current literature on myasthenia gravis management in pregnancy.
- Analysis of therapeutic strategies, including pharmacologic and non-pharmacologic interventions.
- Discussion of delivery considerations and anesthesia options.
Main Results:
- Anticholinesterase drugs are the primary treatment for MG in pregnancy.
- Corticosteroids, azathioprine, and cyclosporine A are options for refractory symptoms.
- Mycophenolate mofetil and methotrexate should be avoided.
- Plasmapheresis and IVIg are effective for MG crisis.
- Epidural anesthesia and selective Cesarean section are recommended.
Conclusions:
- Myasthenia gravis can be effectively managed during pregnancy with appropriate therapies.
- Close collaboration between gynecologists and neurologists is crucial for optimal patient outcomes.
- Women with MG should be encouraged to plan pregnancies with medical guidance.